Clinical Trial Update: Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating interleukin-2 in combination with an unspecified monoclonal antibody in patients with bladder cancer, kidney cancer, or lung cancer tha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Kidney Cancer
• Lung Cancer

Drugs mentioned

• Monoclonal antibody therapy (unspecified)
• Proleukin (aldesleukin)

Snippet

Sponsor: EMD Serono | Conditions: Bladder Cancer, Kidney Cancer | Phase 1 | Status: COMPLETED